HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
Asia Biotech Live
LATEST UPDATES » Vol 24, No 01, January 2020 – Empowering the Patient - Personalization of Diabetes Management       » First of its kind Human Heart-in-a-Jar Model for therapeutic solutions       » China's National Vaccine Tracking System set to be completed in 2020       » China's amended drug administration law kicks in       » Human activity puts Chinese plant biodiversity at risk, study finds       » Contributory effects of each brain cell type in development of Alzheimer's Disease      
Vol 24, No. 01, January 2020For e-subscribers (PDF)
INSIDE INDUSTRY
First of its kind Human Heart-in-a-Jar Model for therapeutic solutions
Global stem cell biotechnology company, Novoheart collaborates with AstraZeneca to co-develop the first Human Heart-in-a-Jar Model of heart failure to provide a unique solution for future assessment of novel therapeutics.

Heart failure (HF) is a global pandemic due to its high prevalence of an estimated 64.3 million cases worldwide in 2017 and the trend continues to increase year on year. This represents an annual global economic burden of disease of over US$100 billion. One form of HF is heart failure with preserved ejection fraction (HFpEF) that accounts for 50 percent of HF cases. Despite this major and growing public health problem worldwide, its pathological mechanisms and diverse aetiology is poorly understood.

These complexities thus demands the need for accurate models of the disease in order to provide an effective tool for preclinical testing of the efficacy of therapeutic solutions. In view of this, Novoheart and the Cardiovascular, Renal and Metabolism therapy area of AstraZeneca aims to establish a new in vitro model, leveraging Novoheart’s proprietary 3-D human ventricular cardiac organoid chamber (hvCOC) technology, that reproduces key phenotypic characteristics of HFpEF.

Also known as “human heart-in-a-jar”, the hvCOC is the only human engineered heart tissue available on the market to date that enables clinically informative assessment of human cardiac pump performance including ejection fraction and developed pressure. Unlike animal models, engineered hvCOCs can be fabricated with specific cellular and matrix compositions, and patient-specific human induced pluripotent stem cells (iPSCs), that allow control over their physical and mechanical properties to mimic those observed in HFpEF patient hearts.

“We are delighted to partner with AstraZeneca, an organization which has long invested in cardiovascular research and is committed to bringing new therapeutic solutions to patients with heart failure,” said Novoheart CSO, Dr. Kevin Costa. “We look forward to co-developing this new HFpEF hvCOC model into a powerful new tool in the worldwide battle against heart failure.”

Novoheart will exclusively own the intellectual property rights to the newly developed HFpEH hvCOC model.

Regina Fritsche Danielson, Senior Vice President, Head of Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, said, “There are significant unmet treatment needs in patients with heart failure with preserved ejection fraction. By combining Novoheart’s proprietary hvCOC model with our expertise in heart failure, we aim to create the first in vitro model reproducing phenotypic characteristics of heart failure with preserved ejection fraction. This could bridge the gap between in vivo animal models and clinical trials to help accelerate the drug discovery process by providing human-specific preclinical data.”

Click here for the complete issue.

NEWS CRUNCH  
news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions
news 2nd China Pharma Digital Innovation Summit to be held in Shanghai
news 2nd China Healthcare Digital Innovation Summit to be held in Shanghai
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy